HPLC · CoA
What Is Cagrilintide, and What Is Its Mechanism of Action?
Explainer · 7 min read · Updated 30 September 2026
Cagrilintide is a synthetic, long-acting amylin analogue that activates the three amylin receptors, AMY1, AMY2 and AMY3, and the calcitonin receptor on its own. Each amylin receptor is the calcitonin receptor paired with a RAMP accessory protein. The parent hormone, amylin, has 37 residues and is released with insulin by pancreatic beta cells. Cagrilintide carries a fatty diacid that binds serum albumin, extending circulation to days, and sequence substitutions that prevent the fibril formation that makes native amylin difficult to handle.
What Is Amylin, and Why Was an Analogue Needed?
Amylin is a 37 residue pancreatic hormone, and an analogue was needed because the native peptide forms aggregates and leaves the circulation in minutes. Also called islet amyloid polypeptide, it is released alongside insulin after a meal. The human sequence has a disulfide bridge between the cysteines at positions 2 and 7 and an amidated C-terminus. Physiology research associates it with slower gastric emptying, a reduced post-meal glucagon rise and satiety signalling through the hindbrain.
Native human amylin forms amyloid fibrils, which block equipment and produce inconsistent concentrations. An earlier analogue, pramlintide, reduced aggregation by introducing prolines at positions 25, 28 and 29, taken from the rat sequence, but it remained short-acting. Cagrilintide was engineered to address both limitations in one molecule.
What Is Cagrilintide Built From?
Cagrilintide is built from an amylin backbone with fibril-suppressing amino acid substitutions plus acylation, according to the 2021 design paper in the Journal of Medicinal Chemistry. A long-chain fatty diacid is attached to the backbone through a spacer. That chain binds serum albumin reversibly, shielding the peptide from proteolysis and renal filtration. The finished molecule has a mass of roughly 4,400 daltons.
How Does Cagrilintide Act on Amylin Receptors?
Cagrilintide acts as an agonist at all three amylin receptors and at the calcitonin receptor, which is why the literature classes it as a dual amylin and calcitonin receptor agonist, or DACRA. Amylin receptors are unusual because each is assembled from two proteins. The core is the calcitonin receptor, a class B G protein-coupled receptor that on its own responds mainly to calcitonin. When a receptor activity-modifying protein, or RAMP, associates with it at the cell surface, the complex becomes an amylin receptor. Three RAMPs give three amylin receptors.
| Receptor | Components | Main ligand preference |
|---|---|---|
| CTR | calcitonin receptor alone | calcitonin |
| AMY1 | calcitonin receptor plus RAMP1 | amylin, also CGRP |
| AMY2 | calcitonin receptor plus RAMP2 | amylin |
| AMY3 | calcitonin receptor plus RAMP3 | amylin |
Receptor activation couples mainly to Gs and cyclic AMP. The most studied sites of action lie in the hindbrain, particularly the area postrema and the nucleus of the solitary tract, where a permeable blood-brain barrier allows circulating peptides to reach neurons directly.
Laboratories use cagrilintide research peptide vials to characterise amylin receptor pharmacology in transfected cell lines, to compare acylated and native amylin, to measure gastric emptying and satiety signalling in animal models, and to examine how the amylin pathway interacts with incretin receptors.
Is Cagrilintide the Same as Semaglutide?
Cagrilintide is not the same as semaglutide: cagrilintide is an amylin analogue, while semaglutide is a GLP-1 analogue acting on a different receptor. The two are frequently discussed together because they have been paired in clinical research, but they belong to separate hormone families.
| Feature | Cagrilintide | Semaglutide |
|---|---|---|
| Parent hormone | amylin (37 residues) | GLP-1 (7-37 fragment, 31 residues) |
| Receptor targets | AMY1, AMY2, AMY3 and calcitonin receptor | GLP-1 receptor |
| Receptor structure | calcitonin receptor plus RAMP | single class B receptor |
| Half-life extension | fatty diacid, albumin binding | C18 fatty diacid, albumin binding, Aib at position 8 |
| Approximate mass | about 4,400 Da | about 4,114 Da |
| Key brain region studied | area postrema, hindbrain | hypothalamus and hindbrain |
Both molecules extend circulation with a fatty acid chain that binds albumin, which allows the same administration schedule in study designs. Their signals originate at different receptors in different tissues, and whether those signals are additive is the central question of combination research. That work was reported as a phase 1b study in The Lancet in 2021 and as a phase 3 trial in NEJM in 2025.
Can Cagrilintide Be Studied With Retatrutide?
Cagrilintide can be studied with retatrutide, and we supply the pair as a single preparation for that purpose. The retatrutide and cagrilintide 15mg blend combines the amylin analogue with a single molecule that activates GLP-1, GIP and glucagon receptors. No published study has examined that exact combination, so work with it draws on the pharmacology of each component. The label and certificate for each lot state the milligram content of each peptide.
For single-pathway designs, separate retatrutide vials and the amylin analogue alone allow researchers to set their own ratios and controls. The complete list is in our metabolic research peptides.
How Is Cagrilintide Stored and Reconstituted in the Laboratory?
Cagrilintide is stored as sealed lyophilised powder at minus 20 degrees C and, once reconstituted with bacteriostatic water, held at 2 to 8 degrees C and used within 28 days. Our vials are filled at 5mg and 10mg. The 28 day window follows the standard in-use convention for a multi-use vial preserved with benzyl alcohol.
| Cagrilintide fill | Bacteriostatic water | Strength | Content of a 10 unit measure |
|---|---|---|---|
| 5 mg vial | 2.5 mL water | 2 mg/mL | 200 mcg |
| 5 mg vial | 5 mL water | 1 mg/mL | 100 mcg |
| 10 mg vial | 2.5 mL water | 4 mg/mL | 400 mcg |
| 10 mg vial | 5 mL water | 2 mg/mL | 200 mcg |
Lipidated peptides can adsorb to plastic and glass at low concentrations, so gentle swirling and a fully clear solution before use are particularly important. For a first stock, the cagrilintide starter kit supplies the 5mg vial together with bacteriostatic water (3 mL), ten 0.5 mL syringes and twenty swabs. Purity for every lot reads 98% or higher on HPLC, mass spectrometry verifies identity, and the certificate of analysis travels with the vial.
What Is Cagrilintide Used For in Research?
Cagrilintide is used in research because it reaches a receptor family that incretin agonists do not, and it does so with stable, reproducible solution behaviour. Four properties define its place in study design.
- It activates amylin and calcitonin receptors, which GLP-1, GIP and glucagon agonists do not engage.
- Its extended circulation allows infrequent administration schedules in animal models.
- Its resistance to fibril formation makes solutions more reproducible than native amylin.
- Its non-selective profile across amylin and calcitonin receptors is itself a variable that can be tested against more selective tools.
Our recommendation: when a study must separate amylin signalling from incretin signalling, run the amylin analogue as a single vial first and add a combination arm only afterwards, so each receptor family has its own baseline. Published study designs are collected in our cagrilintide study library.
Questions about what is cagrilintide
Sources
- Development of cagrilintide, a long-acting amylin analogue. Journal of Medicinal Chemistry. 2021.
Written by the Macropus Peptides technical team for in-vitro laboratory research reference. Not medical advice; products are not for human or veterinary use and are sold to buyers aged 18 and over.